Compare LFMD & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFMD | HUMA |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | United States |
| Employees | 384 | 220 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 190.9M | 185.4M |
| IPO Year | N/A | N/A |
| Metric | LFMD | HUMA |
|---|---|---|
| Price | $3.71 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $9.14 | ★ $9.29 |
| AVG Volume (30 Days) | 1.2M | ★ 8.0M |
| Earning Date | 03-09-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.11 | N/A |
| Revenue Next Year | $20.07 | $731.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $0.70 |
| 52 Week High | $15.34 | $2.93 |
| Indicator | LFMD | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 31.26 |
| Support Level | $3.43 | N/A |
| Resistance Level | $4.20 | $1.30 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 6.89 | 2.03 |
LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.